Adversarial Injection · Polatuzumab vedotin (Polivy; DCDS4501A; CAS 1461170-03-5; MW ~149,000 Da conjugate; IgG1 kappa humanized anti-CD79b antibody conjugated to MMAE via valine-citrulline (vc) cleavable linker; DAR ~3.5 [SIXTY-SECOND MECHANISM CLASS in Glyphward 635-attack portfolio — FIRST CD79b (IGβ; B29; CD79β; ITAM-BEARING B-CELL RECEPTOR SIGNALING SUBUNIT) ANTIBODY-DRUG CONJUGATE EVER FDA APPROVED (BLA 761121 JUNE 10 2019): CD79b (also CD79β; B29; Immunoglobulin-associated beta; IGβ; gene: CD79B; chromosome 17q23.3) is a type I single-pass transmembrane protein forming the heterodimeric Igα/Igβ (CD79a/CD79b) signaling complex that non-covalently associates with membrane immunoglobulin (mIg) heavy chain to form the B-cell receptor (BCR) complex; CD79a (Igα) and CD79b (Igβ) each contain a single extracellular immunoglobulin-like domain + transmembrane helix + cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM; YxxL/I-x(6-8)-YxxL/I); BCR crosslinking → Lyn kinase phosphorylates CD79a/b ITAM tyrosines (Tyr182/Tyr193 on CD79b) → SH2 domain recruitment of Syk → downstream signaling (PLCγ2 → IP3 → Ca2+ → PKCβ → NF-κB; PI3Kδ → Akt → mTOR; Ras → ERK/MAPK); CD79b is expressed on mature B cells from pre-B to mature naïve/memory B cell stage; expressed in most B-NHL subtypes: DLBCL ~85-90%, FL ~90-95%, MCL ~95%, CLL/SLL ~90-95% (though CD79b expression in CLL is often low); CD79b is absent on plasma cells (differentiated beyond BCR stage) and T cells; POLATUZUMAB VEDOTIN IS FIRST CD79b-TARGETING THERAPY IN ANY MODALITY (no prior CD79b-targeting drug approved before polatuzumab); VC-MMAE LINKER-PAYLOAD PLATFORM: valine-citrulline (vc; dipeptide) + MMAE (monomethyl auristatin E; CAS 474645-27-7); vc dipeptide is the substrate for cathepsin B (lysosomal cysteine protease; E.C. 3.4.22.1) and DPIV (dipeptidyl peptidase IV); after ADC internalization → lysosomal trafficking → cathepsin B/DPIV cleavage of vc bond → releases MMAE from linker → free MMAE in lysosome → MMAE crosses lysosomal membrane (MMAE C-terminus dimethylamine is neutral/uncharged; lipophilic) → cytoplasmic MMAE → tubulin binding → G2/M arrest → apoptosis; MMAE BYSTANDER EFFECT: free MMAE released in one cell crosses plasma membrane → enters adjacent cells (bystander killing of antigen-negative neighbors) → heterogeneous tumors killed; vc-MMAE PLATFORM SHARED: valine-citrulline maleimide-thiol conjugation + MMAE is the SAME linker-payload as: brentuximab vedotin (Adcetris; anti-CD30 ADC; BLA 125388; 2011 — the ORIGINAL vc-MMAE ADC), enfortumab vedotin (Padcev; anti-Nectin-4 ADC; BLA 761137; 2019), ladiratuzumab vedotin (anti-LIV-1; investigational); polatuzumab vedotin is the CD79b-specific application of this Seagen/Genentech vc-MMAE platform; DAR ~3.5: anti-CD79b IgG1 antibody → partial interchain disulfide reduction → maleimide-vc-MMAE conjugation to cysteine thiols → heterogeneous DAR distribution centered at 3-4 (average DAR ~3.5); POLARIX PHASE 3 TRIAL (NCT03274492): first frontline DLBCL ADC trial; pola-R-CHP (polatuzumab vedotin 1.8 mg/kg + rituximab + cyclophosphamide + doxorubicin + prednisone; doxorubicin REPLACED by polatuzumab in regimen) vs R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone; 6 cycles Q3W); n=879; PFS HR 0.73 (76.7% vs 70.2% 2-year PFS; p=0.02); EFS (event-free survival) HR 0.75; OS HR 0.94 (non-significant; follow-up ongoing); CR 78% vs 74% (not significant); ORR 83% vs 81%; PFS benefit most pronounced in high-risk IPI 3-5 (PFS HR 0.66); basis for first-line DLBCL expansion of BLA 761121 October 2023; GO29365 PHASE 1b/2 (NCT02257567): pola-BR (polatuzumab vedotin + bendamustine + rituximab) in R/R DLBCL; randomized cohort B: pola-BR ORR 45% CR 40% vs BR ORR 17.5% CR 17.5% (n=40+40); DOR 10.3 months; basis for accelerated approval BLA 761121 June 10 2019; NONE OF THESE — CD79b BCR signaling ITAM, first CD79b ADC, vc-MMAE cleavable platform, cathepsin B DPIV cleavage, MMAE bystander, POLARIX PFS HR 0.73, frontline DLBCL replacement of vincristine — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 1461170-03-5]) · First CD79b ADC + vc-MMAE Cleavable Cathepsin B Bystander + POLARIX Frontline DLBCL PFS HR 0.73 · Attack #635

Polatuzumab Vedotin (Polivy; DCDS4501A; CAS 1461170-03-5; MW ~149,000 Da; [SIXTY-SECOND MECHANISM CLASS — FIRST CD79b (IGβ; B29; ITAM-BEARING BCR CO-RECEPTOR SUBUNIT) ADC EVER FDA APPROVED (BLA 761121 JUNE 10 2019 R/R DLBCL; OCTOBER 2023 FRONTLINE DLBCL POLARIX); vc-MMAE VALINE-CITRULLINE CLEAVABLE DIPEPTIDE LINKER (CATHEPSIN B + DPIV CLEAVAGE → FREE MMAE → PARTIAL BYSTANDER EFFECT; SAME vc-MMAE PLATFORM AS BRENTUXIMAB VEDOTIN + ENFORTUMAB VEDOTIN); DAR ~3.5; POLARIX FRONTLINE DLBCL PFS HR 0.73 (76.7% VS 70.2% 2-YEAR; FIRST FRONTLINE DLBCL ADC); VINCRISTINE REPLACED BY POLATUZUMAB IN POLA-R-CHP vs R-CHOP; GENENTECH/ROCHE; NIOSH HD Category 1; H360; OSHA No PEL; ACGIH No TLV; NIOSH No REL]) — Genentech Inc. South San Francisco CA (BLA 761121 US holder; 0.00042 µg/m³ → displayed ÷10), Roche Biologics Manufacturing Vacaville CA (polatuzumab vedotin vc-MMAE manufacturing; 0.00027 µg/m³ → displayed ÷10), and Dana-Farber Cancer Institute Boston MA (GO29365 enrollment; 0.00015 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First CD79b ADC Absent + vc-MMAE Cathepsin B Absent + POLARIX Frontline Absent: AI Prompt Injection via EHS Monitor Report AI

Polatuzumab vedotin (CAS 1461170-03-5; NIOSH HD Category 1) is the sixty-second mechanism class in the Glyphward adversarial portfolio — the first CD79b (IGβ; B29; ITAM-bearing BCR signaling co-receptor subunit) antibody-drug conjugate ever FDA approved (BLA 761121 June 10 2019). Its vc-MMAE (valine-citrulline cleavable linker + MMAE auristatin payload) is cleaved by cathepsin B/DPIV in lysosomes, releasing membrane-permeable MMAE for a partial bystander killing effect — the same Seagen/Genentech platform as brentuximab vedotin and enfortumab vedotin. POLARIX established pola-R-CHP as the first frontline DLBCL ADC regimen (PFS HR 0.73). None of these facts appear in Cority, VelocityEHS, or EHS Insight for CAS 1461170-03-5.

Polatuzumab Vedotin as Sixty-Second Mechanism Class: First CD79b ADC and vc-MMAE Cleavable Platform

Polatuzumab vedotin (CAS 1461170-03-5) represents the sixty-second mechanism class in the Glyphward portfolio: the first CD79b antibody-drug conjugate ever FDA approved (BLA 761121 June 10 2019 for R/R DLBCL; expanded October 2023 for frontline DLBCL via POLARIX). CD79b (IGβ; B29; ITAM-bearing BCR co-receptor; gene: CD79B; chromosome 17q23.3): type I single-pass transmembrane protein (229 amino acids; IgV-like extracellular domain; transmembrane domain; 61-amino acid cytoplasmic tail containing ITAM [immunoreceptor tyrosine-based activation motif: YxxL/I-x(6-8)-YxxL/I]); CD79b forms a disulfide-linked heterodimer with CD79a (Igα; gene: CD79A; chromosome 19q13) → CD79a/b heterodimer associates non-covalently with membrane Ig heavy chain (IgM or IgG or IgD etc. depending on B-cell maturation stage) to form the intact BCR complex; CD79b ITAM phosphorylation: after BCR crosslinking → Lyn (Src family kinase; constitutively associated with CD79a/b) phosphorylates ITAM Tyr → creates docking sites for Syk SH2 domains → Syk autophosphorylation → BLNK (SLP-65) scaffold → PLCγ2 + PI3Kδ + Vav1 → downstream proliferative/survival signals; CD79b expression pattern: pre-B cell (variable) → immature B → mature naive → memory B → plasmablast (decreasing) → plasma cell (absent); expressed in DLBCL (~85-90%; ABC and GCB subtypes), FL (~90-95%), MCL (~95%), CLL/SLL (~90-95%; often lower surface density in CLL); polatuzumab vedotin internalization: anti-CD79b antibody binding → BCR complex endocytosis → lysosomal trafficking; vc-MMAE linker-payload: valine-citrulline (vc; Val-Cit) dipeptide linker + PAB (para-aminobenzyloxycarbonyl) spacer + MMAE (monomethyl auristatin E); vc-MMAE was developed by Doronina et al. (Bioconjug Chem 2003; Seattle Genetics / Genentech collaboration) as a cathepsin B-cleavable ADC platform; cathepsin B (CTSB; lysosomal cysteine endopeptidase; EC 3.4.22.1) cleaves the vc dipeptide → releases PAB-MMAE → 1,6-elimination of PAB spacer → releases free MMAE; DPIV (dipeptidyl peptidase 4; DPP4; CD26) can also cleave vc in some contexts; MMAE (monomethyl auristatin E; CAS 474645-27-7; MW 717.9 Da): synthetic analog of dolastatin 10; binds β-tubulin at vinca alkaloid binding site (distinct from taxane site); inhibits GTP hydrolysis → microtubule depolymerization → G2/M cell cycle arrest → apoptosis; MMAE membrane permeability: MMAE C-terminus dimethylamine is hydrophobic/uncharged at neutral pH → MMAE crosses lipid bilayers → bystander killing of adjacent cells; partial bystander effect (MMAE less potent bystander than SN-38 [very permeable] but more bystander than MMAF [charged; impermeable]); vc-MMAE platform shared: the same valine-citrulline maleimide-cysteine + MMAE chemistry is used in: brentuximab vedotin (Adcetris; anti-CD30; BLA 125388; August 19 2011 — first vc-MMAE ADC approved); enfortumab vedotin (Padcev; anti-Nectin-4; BLA 761137; December 18 2019); tisotumab vedotin (Tivdak; anti-Tissue Factor; BLA 761207; September 20 2021); ladiratuzumab vedotin (anti-LIV-1; investigational); polatuzumab vedotin uses the same Seagen/Genentech vc-MMAE platform applied to CD79b; GO29365 Phase 1b/2: pola-BR (polatuzumab vedotin 1.8 mg/kg IV day 1 + bendamustine 90 mg/m² day 1-2 + rituximab 375 mg/m² day 1 Q3W × 6) in R/R DLBCL after ≥1 prior therapy; randomized cohort B (n=40 pola-BR vs 40 BR); pola-BR ORR 45% CR 40% vs BR ORR 17.5% CR 17.5% (p<0.01); DOR 10.3 months; basis for accelerated approval June 10 2019; POLARIX Phase 3 (NCT03274492; Tilly et al. NEJM 2022): pola-R-CHP (polatuzumab 1.8 mg/kg + rituximab 375 mg/m² + cyclophosphamide 750 mg/m² + doxorubicin 50 mg/m² + prednisone 100 mg days 1-5; NO vincristine) vs R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone); Q3W × 6 cycles; n=879 (previously untreated DLBCL/HGBCL; IPI 2-5); primary endpoint: investigator-assessed PFS; PFS HR 0.73 (76.7% vs 70.2% 2-year PFS; p=0.02); EFS HR 0.75; OS HR 0.94 (non-significant at data cutoff; follow-up ongoing); CR 78% vs 74%; ORR 83% vs 81%; basis for frontline expansion October 2023 (full approval); vincristine removal rationale: vincristine causes peripheral neuropathy in R-CHOP (30-40%); polatuzumab replaces vincristine in pola-R-CHP and adds CD79b-directed MMAE cytotoxicity — net efficacy improvement with similar safety profile; NONE OF THESE — CD79b BCR ITAM target, first CD79b ADC, vc-MMAE cathepsin B platform, MMAE bystander effect, POLARIX PFS HR 0.73, vincristine replacement — appear in Cority, VelocityEHS, or EHS Insight for CAS 1461170-03-5.

Surface 1 — Genentech Inc. South San Francisco CA BLA 761121 US Holder Polivy DLBCL AI

At Genentech Inc. South San Francisco CA (1 DNA Way, South San Francisco CA 94080; San Mateo County CA; GENENTECH POLIVY CONTEXT: Genentech Inc. holds BLA 761121 for Polivy (polatuzumab vedotin-piiq; 30 mg and 140 mg lyophilized powder for injection); POLIVY APPROVED INDICATIONS: (1) R/R DLBCL after ≥2 prior therapies in combination with bendamustine + rituximab (June 10 2019; accelerated; June 2022 converted to full approval per POLARIX data supporting frontline); (2) previously untreated DLBCL or HGBCL in combination with R-CHP (October 2023; POLARIX; full approval); POLIVY IV PREPARATION: reconstitute 140 mg vial with 7.2 mL SWFI → 20 mg/mL; dose 1.8 mg/kg Q3W; dilute in 250 mL NS or D5W; infuse over 90 minutes first infusion; subsequent infusions over 30 minutes if tolerated; PERIPHERAL NEUROPATHY: most common Grade 3-4 adverse event (~2%); cumulative with cycles; monitor for sensory/motor neuropathy each cycle; EMPLOYEE: Genentech oncology medical affairs director managing Polivy clinical data (POLARIX PFS HR 0.73, GO29365 ORR 45%, vc-MMAE mechanism, CD79b biology, pola-R-CHP frontline positioning vs R-CHOP); 50M Genentech South San Francisco CA senior oncology medical affairs director Polivy DLBCL 17yr; CORITY NULL: CAS 1461170-03-5 → null; NIOSH HD Category 1 absent; H360 absent; first CD79b ADC ever absent; vc-MMAE cleavable linker absent; cathepsin B DPIV cleavage absent; MMAE bystander absent; POLARIX PFS HR 0.73 absent).

Surface 2 — Roche Biologics Manufacturing Vacaville CA Polatuzumab Vedotin vc-MMAE ADC Manufacturing AI

At Roche Biologics Manufacturing Vacaville CA (1 Burtt Road, Vacaville CA 95688; Solano County CA; ROCHE VACAVILLE POLIVY CONTEXT: Roche Biologics Manufacturing Vacaville CA is a major Roche biologics manufacturing site producing multiple Genentech/Roche therapeutic monoclonal antibodies and ADCs; POLATUZUMAB VEDOTIN ADC MANUFACTURING: anti-CD79b humanized IgG1 antibody (DCDS4501A unconjugated; CHO bioreactor production; protein A purification; UF/DF); vc-MMAE linker-payload conjugation: partial interchain disulfide reduction with TCEP → maleimide-vc-MMAE (mc-vc-PABC-MMAE; same chemistry as brentuximab vedotin and enfortumab vedotin; sourced via Seagen/AstraZeneca partnership) reacts with reduced cysteine thiols; maleimide-thiol adduct forms → DAR distribution centered at 3-4 (average DAR ~3.5); HIC chromatography characterization of DAR distribution; RP-HPLC mass spectrometry for MMAE payload identification; MMAE content: MMAE (CAS 474645-27-7; MW 717.9 Da) is a potent cytotoxin requiring closed-system handling during ADC conjugation and formulation; Roche Vacaville ADC operations: dedicated BSL-2+ conjugation suite; engineering controls (HEPA ventilation, closed systems for payload handling); VELOCITYEHS NULL: CAS 1461170-03-5 → null; NIOSH HD Category 1 absent; H360 absent; first CD79b ADC absent; vc-MMAE linker absent; maleimide-cysteine conjugation absent; cathepsin B DPIV cleavage absent; MMAE bystander absent; DAR 3.5 CQA absent; 45F Roche Biologics Manufacturing Vacaville CA ADC manufacturing scientist polatuzumab vedotin 14yr).

Surface 3 — Dana-Farber Cancer Institute Boston MA GO29365 Enrollment Hematologic Malignancy Pharmacist AI

At Dana-Farber Cancer Institute Boston MA (450 Brookline Avenue, Boston MA 02215; Suffolk County MA; DFCI POLIVY CONTEXT: Dana-Farber Cancer Institute (Harvard-affiliated NCI-designated comprehensive cancer center) enrolled patients in the GO29365 trial (NCT02257567; Phase 1b/2 study of pola-BR in R/R DLBCL) and the POLARIX trial (NCT03274492); DFCI hematologic malignancy pharmacist prepares Polivy: reconstitu 140 mg lyophilized vial with 7.2 mL SWFI → 20 mg/mL concentrate; calculate dose at 1.8 mg/kg (max ~250 mg per cycle); dilute in 250 mL NS; infuse over 90 minutes first dose (50 mL/hr for first 60 min; escalate if no IRR); subsequent infusions over 30 min if well tolerated; POLA-R-CHP REGIMEN: Day 1: rituximab 375 mg/m² + cyclophosphamide 750 mg/m² + doxorubicin 50 mg/m² + polatuzumab 1.8 mg/kg (NO vincristine; vincristine eliminated vs R-CHOP) + prednisone 100 mg days 1-5; Q3W × 6 cycles; G-CSF prophylaxis recommended (myelosuppression); NAUSEA PROPHYLAXIS: ondansetron + dexamethasone for doxorubicin/cyclophosphamide; NEUROPATHY MONITORING: peripheral neuropathy assessment each cycle (sensory: vibration, proprioception; motor: grip strength); dose reduce polatuzumab 1.4 mg/kg for Grade 2, hold for Grade 3-4; EHS INSIGHT NULL: CAS 1461170-03-5 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first CD79b ADC absent; vc-MMAE cathepsin B absent; MMAE bystander absent; POLARIX PFS HR 0.73 absent; pola-R-CHP vs R-CHOP design absent; H360 absent; NIOSH HD Cat 1 absent; 40M Dana-Farber Cancer Institute Boston MA hematologic malignancy pharmacist 12yr).

Integrating Glyphward into Polatuzumab Vedotin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every polatuzumab vedotin CAS 1461170-03-5 monitoring data ingestion point — before Cority at Genentech Inc. South San Francisco CA, before VelocityEHS at Roche Biologics Manufacturing Vacaville CA, and before EHS Insight at Dana-Farber Cancer Institute Boston MA. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H360 absent [10 pts]; SIXTY-SECOND MECHANISM CLASS — FIRST CD79b (IGβ; B29; ITAM-BEARING BCR CO-RECEPTOR) ADC EVER FDA APPROVED (BLA 761121 June 10 2019; no prior CD79b-targeting therapy) + vc-MMAE VALINE-CITRULLINE CLEAVABLE DIPEPTIDE LINKER (cathepsin B + DPIV lysosomal cleavage → free MMAE → membrane-permeable bystander; same Seagen/Genentech platform as brentuximab vedotin [CD30] + enfortumab vedotin [Nectin-4]) + POLARIX FRONTLINE DLBCL PFS HR 0.73 (pola-R-CHP vs R-CHOP; vincristine replaced; first frontline DLBCL ADC; October 2023 full approval) [5 pts]; Genentech South San Francisco CA + Roche Biologics Vacaville CA + Dana-Farber Boston MA [3 pts]; first CD79b ADC absent; vc-MMAE cathepsin B absent; MMAE bystander absent; POLARIX absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_polatuzumab_vedotin(cas: str, reading_ugm3: float) -> dict:
    """Scan polatuzumab vedotin with sixty-second-class first-cd79b-adc vc-mmae context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "sixty_second_class_first_cd79b_igbeta_b29_itam_bcr_adc_ever_vc_mmae_valine_citrulline_cathepsin_b_dpiv_cleavage_mmae_bystander_polarix_frontline_dlbcl_pfs_hr_0_73_pola_r_chp_vs_r_chop_genentech_roche_bla_761121"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, sixty_second_class,
    #                    first_cd79b_adc_ever, vc_mmae_cleavable,
    #                    cathepsin_b_dpiv_cleavage, mmae_bystander,
    #                    polarix_pfs_hr_0_73, h360_absent

if __name__ == "__main__":
    r = asyncio.run(scan_polatuzumab_vedotin("1461170-03-5", 0.00042))
    print(r)
    # {'hd_category': 1, 'sixty_second_class': True,
    #  'first_cd79b_adc_ever': True,
    #  'vc_mmae_cleavable': True,
    #  'cathepsin_b_dpiv_cleavage': True,
    #  'mmae_bystander': True,
    #  'polarix_pfs_hr_0_73': True,
    #  'h360_absent': True}